NoteHC Andersen Capital receives payment from ALK-Abelló for a DigitalIR/Corporate Visibility agreement. See disclaimer.

Log in to your Inderes Free account to see all free content on this page.

ALK-Abelló

138.7

DKK

-0.93 %

Less than 1K followers

ALK B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-0.93%

-12.05%

-12.82%

-11.71%

-21.15%

+10.96%

-4.34%

+98.85%

+302.03%

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.

Market cap

30.91B DKK

Turnover

23.46M DKK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

6.5.

2025

Interim report Q1'25

21.8.

2025

Interim report Q2'25

13.11.

2025

Interim report Q3'25

All

Press releases

ShowingAll content types

Regulatory press release3/13/2025, 5:06 PM

Annual General Meeting in ALK-Abelló A/S held on 13 March 2025

Press release3/7/2025, 1:34 PM

ACARIZAX® approved in Canada for treatment of young children

Regulatory press release3/4/2025, 9:20 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/27/2025, 8:51 PM

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Regulatory press release2/21/2025, 2:59 PM

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

Regulatory press release2/19/2025, 1:46 PM

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Regulatory press release2/19/2025, 6:32 AM

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Press release2/12/2025, 4:02 PM

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Press release1/30/2025, 9:13 AM

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

Press release12/20/2024, 4:08 PM

ALK – Financial calendar for the 2025 financial year

Regulatory press release12/18/2024, 11:51 AM

Positive results advance peanut tablet to phase II development

Regulatory press release12/12/2024, 3:06 PM

ACARIZAX® approved in Europe for treatment of young children

Press release11/27/2024, 12:45 PM

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

Regulatory press release11/14/2024, 6:30 AM

Nine-month interim report (Q3) 2024 (unaudited)

Regulatory press release11/9/2024, 10:29 PM

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Press release11/7/2024, 11:08 AM

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

Regulatory press release8/27/2024, 3:30 PM

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Regulatory press release8/22/2024, 3:49 PM

Six-month interim report (Q2) 2024

Regulatory press release8/22/2024, 3:38 PM

ALK upgrades its full-year revenue and earnings outlook

Press release8/14/2024, 9:58 AM

Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.